Adjustments for Non-Cash Items

Stock-Based Compensation

Changes in Working Capital

Capital Expenditures (CapEx)

Proceeds from Debt

Repayments of Debt

Share Repurchases

Dividend Payments

Net Change in Cash

897024ce5a230257def4f9dc4afe40cbecf2f9643bc96bd1eaf53fbf647e6f17

953d5f08a800b094a8769460f5f03b5e54d3cf936fa77e7223b987d63f1cb8a7

Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

SG&A [USD, Millions]

R&D [USD, Millions]

D&A [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

EPS - Basic [USD]

EPS - Diluted [USD]

24f11be1fbfd9cb2efcb9fa090aa6ff6ba43f17e4cd11be59f42da6aa626a094

039cf46da4178cf1bfa5c27cfc184e3e55a436125abb107348ae6a2824641d5f

United States

Europe, Middle East, Africa

China

Japan

Latin America

Asia Pacific

Other

Total Revenue

ee888a0544e6c17830ddb6b8e1ce1026ea722c5be56034f9bd46c1f7a20492c6

Number of tumor types for Keytruda in the U.S. (tumor types)

Number of tumor-agnostic indications for Keytruda in the U.S. (indications)

0ab994adad13328a6cef2270ba622f0eabc600ef1d96a5c8e757f14e79fd19f6

Cash and cash equivalents (USD, millions)

Short-term investments (USD, millions)

Accounts receivable (USD, millions)

Inventories (USD, millions)

Other current assets (USD, millions)

Total current assets (USD, millions)

Investments (USD, millions)

Property, Plant and Equipment, net (USD, millions)

Goodwill (USD, millions)

Other Intangibles, Net (USD, millions)

Other Assets (USD, millions)

Total Assets (USD, millions)

Loans payable and current portion of long-term debt (USD, millions)

Trade accounts payable (USD, millions)

Accrued and other current liabilities (USD, millions)

Income taxes payable (USD, millions)

Dividends payable (USD, millions)

Total current liabilities (USD, millions)

Long-Term Debt (USD, millions)

Deferred Income Taxes (USD, millions)

Other Noncurrent Liabilities (USD, millions)

Common stock (USD, millions)

Other paid-in capital (USD, millions)

Retained earnings (USD, millions)

Accumulated other comprehensive loss (USD, millions)

Total Merck & Co., Inc. stockholders’ equity (Subtotal) (USD, millions)

Less treasury stock, at cost (USD, millions)

Total Merck & Co., Inc. stockholders’ equity (USD, millions)

Noncontrolling Interests (USD, millions)

Total equity (USD, millions)

Total Liabilities and Equity (USD, millions)

e4fcbf015777e125c39cd50b7f17f095eeb510c2b08eb382d859933269a776c2

Sales (USD, millions)

Cost of Sales (USD, millions)

Selling, General and Administrative Expenses (USD, millions)

Research and Development Expenses (USD, millions)

Restructuring Costs (USD, millions)

Other (Income) Expense, Net (USD, millions)

Income Before Taxes (USD, millions)

Taxes on Income (USD, millions)

Net Income (USD, millions)

Net Income Attributable to Noncontrolling Interests (USD, millions)

Net Income Attributable to Merck & Co., Inc. (USD, millions)

Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (USD)

Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (USD)

ae7f6f106796e1436067729717979adadfed74d149c35665ea1803140e89cb80

Merck & Co Inc (MRK)

Financials